Peroxisome proliferatoractivated receptor-γ agonist rosiglitazone reduces secondary damage in experimental spinal cord injury

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 153-161

  Li, Xigong ^a   Du, Junhua ^a   Xu, Sanzhong ^a   Lin, Xiangjin ^a   Ling, Zhiheng ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Inflammation; Neuroprotection; Rosiglitazone; Spinal cord injury

Indexed keywords

INTERLEUKIN 1BETA; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN BAX; PROTEIN BCL 2; ROSIGLITAZONE; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT ANIMAL; ANEURYSM CLIP; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; INFLAMMATION; LAMINECTOMY; LOCOMOTION; NEUROPROTECTION; NONHUMAN; RAT; SHAM PROCEDURE; SPINAL CORD INJURY; SPRAGUE DAWLEY RAT; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; MALE; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; INTERLEUKIN-1BETA; MALE; MOTOR ACTIVITY; PEROXIDASE; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; SPINAL CORD INJURIES; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878408552     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513476601     Document Type: Article

References (34)

1. Rintala DH, Loubser PG, Castro J, et al. Chronic pain in a community-based sample of men with spinal cord injury: prevalence, severity, and relationship with impairment, disability, handicap, and subjective wellbeing. Arch Phys Med Rehabil 1998; 79: 604-614.
2. Kwon BK, Tetzlaff W, Grauer JN, et al. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004; 4: 451-464.
3. Akdemir O, Berksoy I, Karaoǧlan A, et al. Therapeutic efEcacy of Ac-DMQD-CHO, a caspase 3 inhibitor, for rat spinal cord injury. J Clin Neurosci 2008; 15: 672-678.
4. Bartholdi D and Schwab ME. Expression of pro-inFammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci 1997; 9: 1422-1438.
5. Hayashi M, Ueyama T, Nemoto K, et al. Sequential mRNA expression for immediate early genes, cytokines, and neurotrophins in spinal cord injury. J Neurotrauma 2000; 17: 203-218.
6. Wang CX, Olschowka JA and Wrathall JR. Increase of interleukin-1β mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res 1997; 759: 190-196.
7. Jones TB, McDaniel EE and Popovich PG. Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des 2005; 11: 1223-1236.
8. Li GL, Brodin G, Farooque M, et al. Apoptosis and expression of Bcl-2 after compression trauma to rat spinal cord. J Neuropathol Exp Neurol 1996; 55: 280-289.
9. Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997; 17: 5395-5406.
10. Hall ED. The neuroprotective pharmacology of methylprednisolone. J Neurosurg 1992; 76: 13-22.
11. Nadeau S and Rivest S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J Neurosci 2003; 23: 5536-5544.
12. Gerndt SJ, Rodriguez JL, Pawlik JW, et al. Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma 1997; 42: 279-284.
13. Pointillart V, Petitjean ME, Wiart L, et al. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 2000; 38: 71-76.
14. Matsumoto T, Tamaki T, Kawakami M, et al. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine (Phila Pa 1976) 2001; 26: 426-430.
15. Starner CI, Schafer JA, Heaton AH, et al. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008; 14: 523-531.
16. Tolman KG and Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003; 7: 369-379.
17. Kiaei M, Kipiani K, Chen J, et al. Peroxisome proliferator-activated receptorgamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005; 191: 331-336.
18. Dehmer T, Heneka MT, Sastre M, et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation. J Neurochem 2004; 88: 494-501.
19. Victor NA, Wanderi EW, Gamboa J, et al. Altered PPARγ expression and activation after transient focal ischemia in rats. Eur J Neurosci 2006; 24: 1653-1663.
20. Yi JH, Park SW, Brooks N, et al. PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 2008; 1244: 164-172.
21. Basso DM, Beattie MS and Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 1995; 12: 1-21.
22. Lehrke M and Lazar MA. The many faces of PPARγ. Cell 2005; 123: 993-999.
23. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995; 83: 813-819.
24. 2 activates peroxisome proliferator-activated receptor-γ, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2006; 26: 811-820.
25. 2 on early functional recovery from experimental spinal cord injury. Shock 2008; 30: 142-152.
26. McTigue DM, Tani M, Krivacic K, et al. Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury. J Neurosci Res 1998; 53: 368-376.
27. Blight AR. Macrophages and inFammatory damage in spinal cord injury. J Neurotrauma 1992; 9(suppl 1): S83-S91.
28. Kapadia R, Yi JH and Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008; 13: 1813-1826.
29. Charriaut-Marlangue C, Margaill I, Represa A, et al. Apoptosis and necrosis after reversible focal ischemia: an in situ DNA fragmentation analysis. J Cereb Blood Flow Metab 1996; 16: 186-194.
30. Crowe MJ, Bresnahan JC, Shuman SL, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997; 3: 73-76.
31. Kato H, Kanellopoulos GK, Matsuo S, et al. Neuronal apoptosis and necrosis following spinal cord ischemia in the rat. Exp Neurol 1997; 148: 464-474.
32. Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997; 17: 5395-5406.
33. Abe Y, Yamamoto T, Sugiyama Y, et al. Apoptotic cells associated with Wallerian degeneration after experimental spinal cord injury: a possible mechanism of oligodendroglial death. J Neurotrauma 1999; 16: 945-952.
34. Wu CH, Ding XY, Wang HY, et al. Neural apoptosis and apoptosis-related genes in intracerebral hemorrhage patients. Zhonghua Yi Xue Za Zhi 2006; 86: 3073-3076 [in Chinese, English abstract].